Millennium Management »

Inhibikase Therapeutics shares owned by Millennium Management

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Millennium Management from 13F filings

Historical chart of Millennium Management investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Millennium Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Millennium Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $348k 170k 2.05
2025-03-31 $2.0M 914k 2.19
2024-12-31 $462k 142k 3.25

More positions owned by Millennium Management

Ishares Tr Russell 2000 Etf Call Option (IWM)
Ishares Tr Core S&p500 Etf (IVV)
NVIDIA Corporation (NVDA)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Apple Put Option (AAPL)
Wal-Mart Stores Call Option (WMT)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Microsoft Corporation Call Option (MSFT)
Amazon (AMZN)
Meta Platforms Cl A (META)
Broadcom Call Option (AVGO)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Tesla Motors (TSLA)
Alphabet Cap Stk Cl C Put Option (GOOG)
Select Sector Spdr Tr State Street Fin (XLF)

View all positions for Millennium Management

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
ADAR1 Capital Management
Blackstone Group
Siren
Perceptive Advisors
Commodore Capital
Vanguard Group
Nantahala Capital Management
Saturn V Capital Management
BlackRock
Stonepine Capital Management
Integral Health Asset Management
Ameriprise Financial

View all funds holding Inhibikase Therapeutics